When was Metrion Biosciences founded?

Metrion Biosciences was founded in 2015 and raised its 1st funding round 3 years after it was founded.

Where is Metrion Biosciences located?

Metrion Biosciences is headquartered in Cambridge, United Kingdom. It is registered at FIRST FLOOR, BUILDING 2 GRANTA CENTRE, GRANTA PARK,GREAT ABINGTON,CAMBRIDGE,UNITED KINGDOM,CB21 6AL.

Which legal entities is Metrion Biosciences associated with?

Metrion Biosciences is associated with Metrion Biosciences Ltd.

How many employees does Metrion Biosciences have?

As of Apr 30, 2026, the latest employee count at Metrion Biosciences is 42.

Is Metrion Biosciences a funded company?

Metrion Biosciences is a funded company, having raised a total of $8.44M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Feb 05, 2018.

When was the latest funding round of Metrion Biosciences?

Metrion Biosciences' latest funding was a $***** Series B round on Dec 20, 2023, with participation from 2 investors. Its primary sector is Biopharma Outsourcing. In United Kingdom, the Biopharma Outsourcing sector has seen $20.7M in funding in 2026 to date.

What is the annual revenue of Metrion Biosciences?

Annual revenue of Metrion Biosciences is £5.29M as on Dec 31, 2022.

Where does Metrion Biosciences rank among its competitors?

Metrion Biosciences ranks 1st amongst 69 active competitors, of which 18 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Metrion Biosciences, which secured $4.7M in Dec, 2023.

Who are the top competitors of Metrion Biosciences?

Metrion Biosciences' top competitors include Anabios, Global Access Dx and Clyde Biosciences. Among them, Metrion Biosciences secured the most recent funding round in December, 2023.

Metrion Biosciences - 2026 Company Profile, Funding, Competitors & Financials

Metrion Biosciences is a series B company based in Cambridge (United Kingdom), founded in 2015. It operates as a CRO specializing in ion channel screening, cardiac safety profiling and drug discovery services. Metrion Biosciences has raised $8.44M in funding from investors like Maven Capital Partners, o2h ventures and Gresham House Ventures. The company has 69 active competitors, including 18 funded and 9 that have exited. Its top competitors include companies like Anabios, Global Access Dx and Clyde Biosciences.

Company Details

Metrion is a CRO specializing in ion channel screening, cardiac safety profiling and drug discovery services on a fee-for-service or collaboration basis. They offer services such as ion channel screening, cardiac safety panel screening (CiPA and hERG), neuroscience panels (neuroscience-related ion channel screening assays and platforms) and translational assays (phenotypic assays to aid the translation of in vitro cardiac safety and neuroscience data to the preclinical stage). They claim to have over 80 years of combined global ion channel research and drug discovery expertise and also in a wide range of ion channel gene families (Nav, Cav, Kv, hERG, TRP, GluR, nAChR), pain pharmacology, and synaptic transmission and plasticity. The company was formed by a management buyout from Xention Ltd., in October 2015.

Website: metrionbiosciences.com
Email ID: *****@metrionbiosciences.com
Registered Address: FIRST FLOOR, BUILDING 2 GRANTA CENTRE, GRANTA PARK,GREAT ABINGTON,CAMBRIDGE,UNITED KINGDOM,CB21 6AL

Key Metrics

Founded Year

2015

Location

Cambridge, United Kingdom

Stage

Series B

Total Funding

$8.44M in 5 rounds

Latest Funding Round

Series B, Dec 20, 2023, $*****

Investors

Maven Capital Partners & 24 more

Ranked

1^st among 69 active competitors

Annual Revenue

£5.29M as on Dec 31, 2022

Employee Count

42 as on Apr 30, 2026

Similar Companies

Anabios & 76 more

View Metrion Biosciences' full profile

Metrion Biosciences is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Metrion Biosciences Ltd CIN: 9669815 , United Kingdom, Active	Jul 02, 2015	$6.54M (As on Dec 31, 2022)	-

Metrion Biosciences has raised a total funding of $8.44M over 5 rounds. Its first funding round was on Feb 05, 2018. Its latest funding round was a Series B round on Dec 20, 2023 for $*****. 2 investors participated in its latest round. Metrion Biosciences has 5 institutional investors and 20 angel investors.

Here is the list of recent funding rounds of Metrion Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 20, 2023	8700191	Series B	1653058	2910256	9358825	1283382
Apr 06, 2021	1686230	Seed	6512891	5781206	4998298	3893430
Mar 14, 2019	2259074	Seed	9501919	9085023	o2h ventures	5330831

Access funding benchmarks and valuations. Sign up today!

View details of Metrion Biosciences's funding rounds and investors

Metrion Biosciences' employee count trend

Metrion Biosciences has 42 employees as of Apr 26. Here is Metrion Biosciences's employee count trend over the years:

Employee count trend for Metrion Biosciences

Uncover Metrion Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Metrion Biosciences include Anabios, Global Access Dx and Clyde Biosciences. Here is the list of Top 10 competitors of Metrion Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Metrion Biosciences 2015, Cambridge (United Kingdom), Series B	CRO specializing in ion channel screening, cardiac safety profiling and drug discovery services	$8.44M	Gresham House Ventures, Gov & 23 others	47/100
2nd	Anabios 2009, San Diego (United States), Series B	Human tissue and cell provider accelerating drug discovery and development	$24.8M	Tech Coast Angels, Principia SGR & 8 others	45/100
3rd	Global Access Dx 2003, Thurleigh (United Kingdom), Funding Raised	Developer of rapid diagnostic tests and lateral flow technologies	-	-	43/100
4th	Clyde Biosciences 2012, Holytown (United Kingdom), Series A	Boutique Contract Research Organisation for cardiac safety testing	$3.5M	Epidarex Capital, Scottish Enterprise & 3 others	42/100
5th	Jiva Sciences 2015, Bengaluru (India), Funding Raised	Provides research process outsourcing	-	IKP Knowledge Park, KITVEN & 2 others	39/100
6th	Antibody Analytics 2015, Lanark (United Kingdom), Series A	Offers antibody analytics services	-	NorthEdge	39/100
7th	Rules-Based Medicine 2002, Austin (United States), Acquired	Multiplexed biomarker diagnostics.	$25M	Cross Creek, The Stephens Group	38/100
8th	Apconix 2015, Alderley Edge (United Kingdom), Unfunded	Preclinical CRO offering integrated services for toxicology and ion channel studies	-	-	38/100
9th	Optivia Biotechnology 2007, San Francisco (United States), Acquired	CRO offering transporter screening services and solutions for DDI, DMPK, safety and pharmacology	-	HHS	36/100
10th	Pelago Bioscience 2013, Solna (Sweden), Seed	Assay services for use in the determination and quantification of drug-target interactions	-	Impilo, Europa & 1 others	35/100